BRIEF published on 11/13/2025 at 14:50, 10 months 4 days ago Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2025 Résultats Financiers Essais Cliniques Augmentation Des Revenus Technologie DNase Carcinome Pancréatique
PRESS RELEASE published on 11/13/2025 at 14:45, 10 months 4 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 11 months 7 days ago Xenetic Biosciences annonce une offre d'actions de 4,5 millions de dollars Biopharmaceutique Offre D'actions Immuno-oncologie Biosciences Xénétiques Canaccord Genuity
BRIEF published on 10/10/2025 at 15:35, 11 months 7 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
PRESS RELEASE published on 10/10/2025 at 15:30, 11 months 7 days ago Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock Xenetic Biosciences, Inc. announces pricing of underwritten stock offering, aiming to raise $4.5 million for immuno-oncology technologies. Canaccord Genuity acts as bookrunner Xenetic Biosciences Stock Offering Immuno-oncology Technologies Canaccord Genuity S-3 Registration Statement
BRIEF published on 08/13/2025 at 14:05, 1 year 1 month ago Xenetic Biosciences publie ses résultats financiers du deuxième trimestre 2025 Résultats Financiers Biosciences Xénétiques T2 2025 Développement De La DNase I Élargissement Des Partenariats
BRIEF published on 08/13/2025 at 14:05, 1 year 1 month ago Xenetic Biosciences Reports Q2 2025 Financial Results Financial Results Xenetic Biosciences Q2 2025 DNase I Development Partnership Expansions
PRESS RELEASE published on 08/13/2025 at 14:00, 1 year 1 month ago Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q2 2025 results, expands partnership with The Scripps Research Institute for DNase I with CAR T-cell therapies and ends quarter with $4.8M cash Financial Results Xenetic Biosciences DNase I The Scripps Research Institute CAR T-cell Therapies
BRIEF published on 07/30/2025 at 15:05, 1 year 1 month ago Xenetic Biosciences collabore avec PeriNess pour une étude sur le lymphome Immuno-oncologie Étude Clinique Thérapie À La DNase I Cellule CAR-T Lymphome À Grandes Cellules B
BRIEF published on 07/30/2025 at 15:05, 1 year 1 month ago Xenetic Biosciences Collaborates with PeriNess for Lymphoma Study Clinical Study Immuno-oncology DNase I Therapy CAR T-cell Large B Cell Lymphoma
Published on 09/17/2026 at 15:55, 48 minutes ago Empress Announces Agreement to Acquire Tongon Gold Stream and Secures Debt Financing
Published on 09/17/2026 at 15:25, 1 hour 18 minutes ago AIAI Holdings' Constellation Network Launches Dôr Patient Journey with Proactive MD(R), Expanding Transformational AI In Healthcare
Published on 09/17/2026 at 15:00, 1 hour 43 minutes ago Norsemont Hits 41 Meters of 4.59 g/t Gold as Phase 3 Drilling Continues to Expand the Choquelimpie System
Published on 09/17/2026 at 15:00, 1 hour 43 minutes ago ECC Ventures 4 Announces Termination of Agreement With Cambria Gold Mines Inc.
Published on 09/17/2026 at 14:50, 1 hour 53 minutes ago Caldwell Strengthens Human Resources Practice with Addition of Ali Palmer as Partner
Published on 09/17/2026 at 15:30, 1 hour 13 minutes ago Huawei Introduces OceanStor M900 Context Memory Storage to Accelerate AI Inference in Hyperscale Data Centers
Published on 09/17/2026 at 15:08, 1 hour 34 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 09/17/2026 at 15:07, 1 hour 36 minutes ago Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 09/17/2026 at 15:06, 1 hour 37 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
